替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定
取消 确认

识林

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

WHO 制药用水技术报告附录更新及前​后对比

首页 > 资讯 > WHO 制药用水技术报告附录更新及前​后对比

页面比对

出自识林

WHO 制药用水技术报告附录更新及前​后对比
WHO
页面比对
笔记

2012-10-31 ECA

跳转到: 导航, 搜索

WHO TRS 970对制药用水附录内容进行了更新,新版指南"WHO good manufacturing practices: water for pharmaceutical use" 强调指南讨论的范围不包括小规模用水,以及水系统的设计本身对避免系统内微生物生长就很重要,而之前的版本仅将清洁卫生作为衡量指标等等。新旧版指南文件的逐字对比也同时给出。

点击这里查看原文:

The current TRS 970 of the WHO also comprises an updated version of the guideline regarding the manufacture and distribution of water for pharmaceutical use as Annex 3. This revised version contains the same chapters. The modifications are rather based on comments to the previous version which were reviewed and implemented by the WHO Expert Committee. For instance, the range of the guideline's scope was narrowed by excluding the processing small amounts of water in pharmacies. Also new is the indication that already the design of a water system is important for avoiding microbiological growth in the system. Before only the sanitisation was mentioned as measure. The authors also emphasise the importance of the appropriate capacity to ensure a sufficient re-circulation. It is also new that the pharmaceutical manufacturer is in responsible of ensuring that the feed water has drinking water quality. If this is not the case he has to take suitable measures in a step prior to the actual treatment to guarantee this quality. Further, the monitoring of the drinking water quality was amended to consider seasonal effects.

Pharmaceuticals-in-drinking-water.jpg

With regard to purified water (AP) the revision now mentions the possible treatment components (reverse osmosis and EDI). The amendment states (similar to the USP) that warning limits are supposed to be based on operational experience. In reality there are often fixed warning limits - like the 50% from the limit in the pharmacopoeia.

Concerning (bulk) highly purified water (HPW) and (bulk) WFI the revision comprises the amendment that these are to be protected against contamination and microbial growth. Likewise for the sanitisation was added that the removal of any added substances has to be verified. Besides ozone, hydrogen peroxide and peracetic acid were added in the list.

The chapter on appropriate materials was also extended by one paragraph. Here the guideline indicates that none of the materials used should contain chemicals that are extracted by the water. In the case synthetic materials are used the raw materials are supposed to have at least food grade standard.

There are also changes in the chapter on bio contamination control. The recommended temperature of 70-80 °C for hot stored systems was reduced to > 65 °C for example.

In the chapter qualification it was added that also the quality of the feed water needs to be inspected as part of the validation and that this testing is supposed to be continued as part of the routine monitoring. In the chapter inspection of a water system it was further added that an on-site inspection of the treatment as well as of the distribution system and the sampling points should be part of the inspection.

You can find further information in the new version of the Guideline "WHO good manufacturing practices: water for pharmaceutical use" as well as in an exact document comparison.

取自“https://login.shilinx.com/wiki/index.php?title=WHO_%E5%88%B6%E8%8D%AF%E7%94%A8%E6%B0%B4%E6%8A%80%E6%9C%AF%E6%8A%A5%E5%91%8A%E9%99%84%E5%BD%95%E6%9B%B4%E6%96%B0%E5%8F%8A%E5%89%8D%E2%80%8B%E5%90%8E%E5%AF%B9%E6%AF%94”
上一页: EU更新关于变更的法规要求
下一页: 欧盟发布62号令补充文件
相关内容
相关新闻
  • WHO 发布生物类似药问答指南...
  • WHO 发布制药用水 GMP 定稿...
  • FDA 加强对非无菌产品制药用...
  • WHO发布非无菌药品HVAC的GMP指...
  • WHO 发布制药用水 GMP 指南...
热点新闻
  • ICH 发布新 Q1 稳定性指南...
  • 【直播】25年4月全球法规月报...
  • 【识林新文章】中国无菌附录对...
  • VHP(过氧化氢蒸汽)的“脆弱...
  • 【识林新工具】AI知识助手,AI...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP